Cargando…

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries

PATH partnered with the United Nations Population Fund (UNFPA) and country ministries of health (MOHs) to coordinate pilot introductions of subcutaneous depot medroxyprogesterone acetate (subcutaneous DMPA or DMPA-SC, brand name Sayana Press) in Burkina Faso, Niger, Senegal, and Uganda from July 201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stout, Anna, Wood, Siri, Barigye, George, Kaboré, Alain, Siddo, Daouda, Ndione, Ida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Global Health: Science and Practice 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878078/ https://www.ncbi.nlm.nih.gov/pubmed/29602866 http://dx.doi.org/10.9745/GHSP-D-17-00250

Ejemplares similares

Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC)
por: Stout, Anna, et al.
Publicado: (2018)

Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
por: Okegbe, Tishina, et al.
Publicado: (2019)

Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2019)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
por: Odwe, George, et al.
Publicado: (2018)

Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2021)

Health care provider and client experiences of counselling on depot medroxyprogesterone acetate subcutaneous (DMPA-SC) for self-injection in Malawi
por: Porter Erlank, Chelsey, et al.
Publicado: (2023)

A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD
por: Fathizadeh, Nahid, et al.
Publicado: (2011)

Erratum for: Odwe et al., Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
Publicado: (2019)

Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi
por: Burke, Holly M., et al.
Publicado: (2019)

Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study()()()
por: Cover, Jane, et al.
Publicado: (2017)

Scaling up depot medroxyprogesterone acetate (DMPA): a systematic literature review illustrating the AIDED model
por: Curry, Leslie, et al.
Publicado: (2013)

Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
por: Wessels, Jocelyn M., et al.
Publicado: (2021)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
por: Curtis, Kathryn M., et al.
Publicado: (2021)

The potential for intramuscular depot medroxyprogesterone acetate as a self-bridging emergency contraceptive()
por: Schickler, Robyn, et al.
Publicado: (2020)

Comparison of Sexual Dysfunction in Women Using Depo-Medroxyprogesterone Acetate (DMPA) and Cyclofem
por: Ozgoli, Giti, et al.
Publicado: (2015)

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
por: Hapgood, Janet P.
Publicado: (2020)

Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review
por: Aderoba, Adeniyi Kolade, et al.
Publicado: (2023)

High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
por: Bartz, Deborah, et al.
Publicado: (2017)

Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector()
por: Liu, Jenny, et al.
Publicado: (2018)

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()
por: Halpern, Vera, et al.
Publicado: (2023)

Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception()()
por: Onono, Maricianah, et al.
Publicado: (2020)

Adolescent and covert family planning users’ experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate
por: Burke, Holly M., et al.
Publicado: (2020)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection()()()
por: Cover, Jane, et al.
Publicado: (2017)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Patient’s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19()()
por: Smith, Tiffany Joyce, et al.
Publicado: (2023)

Perspectives on DMPA-SC for self-injection among adolescents with unmet need for contraception in Malawi
por: Ali, Gracious, et al.
Publicado: (2023)

Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis
por: Nabhan, Ashraf, et al.
Publicado: (2021)

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review
por: Silva, P., et al.
Publicado: (2018)

Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
por: Upson, Kristen, et al.
Publicado: (2020)

An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract
por: Ayele, Hossaena, et al.
Publicado: (2021)

Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate
por: Bradley, Frideborg, et al.
Publicado: (2022)

What Distinguishes Women Who Choose to Self-Inject? A Prospective Cohort Study of Subcutaneous Depot Medroxyprogesterone Acetate Users in Ghana
por: Nai, Dela, et al.
Publicado: (2022)

DMPA-SC stock: Cross-site trends by facility type
por: Magalona, Sophia, et al.
Publicado: (2022)

Comparison of Two Different Injectable Contraceptive Methods: Depo-medroxy Progesterone Acetate (DMPA) and Cyclofem
por: Veisi, Firoozeh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k7jhc6r1vureb3pkvl81ef7ks3